Articles

Find an Article

Filter articles

Applied Filters

Showing 111 to 120 of 280 results

New rules for SPCs in Spain

Spain27-03-2017José Manuel González

A new law on supplementary protection certificates will be implemented on April 1, with the application, prosecution and maintenance of SPCs taking centre stage. José Manuel González of Clarke, Modet & Co reports.

TPP abandonment: the fallout for biotech and pharma

US15-03-2017Kevin Noonan

President Trump’s decision to pull the US out of the Trans-Pacific Partnership trade deal may have particularly pernicious consequences for the pharmaceutical and biotechnology industries, writes Kevin Noonan of McDonnell Boehnen Hulbert & Berghoff.

Licensing tips from a patent litigator

US21-02-2017Jessamyn Berniker

Anyone drafting patent licence agreements should follow several tips in order to avoid or better prepare for litigation later on, says Jessamyn Berniker of Williams & Connolly.

Biosimilars in Italy: a new regime

Italy10-01-2017Luca Tosoni

Several changes have been made to Italy’s regulatory landscape for biosimilars, as Luca Tosoni of Covington & Burling reports.

The challenges of patenting cell therapies

International22-12-2016Glyn Truscott

A combination of patents, SPCs and regulatory exclusivities should be considered carefully in order to maximise the exclusivity available for cell therapies, as Glyn Truscott of Elkington + Fife explains.

Life sciences transactions: look before you leap

US06-12-2016Karen Mangasarian and Ryan Murphey

Anyone seeking a deal with a life sciences company must understand the value and potential risks of its IP, as Karen Mangasarian and Ryan Murphey of Ropes & Gray explain.

IP Life Sciences Exchange: a preview

Germany07-11-2016

The IP Life Sciences Exchange, an event for senior IP decision-makers from the life sciences sector, will take place on November 15 and 16 in Munich, Germany. LSIPR previews some of the most interesting sessions.

Doubling up: biotech patent examination in Brazil

Brazil25-10-2016Marcelo Oliveira de Souza and Antonio Alexandre Moura dos Santos

Two bodies are responsible for examining biotech patent applications in Brazil, but this approach causes problems, as Marcelo Oliveira de Souza and Antonio Alexandre Moura dos Santos of Di Blasi, Parente & Associados report.

IP service providers: a more cost-effective solution post M&A?

International18-10-2016Melissa Pillote

With specialist IP providers offering post-M&A services at lower cost than traditional law firms, have clients been overspending in the past? Melissa Pillote on behalf of Dennemeyer reports.

Russian patent law: Natural selection

Russia17-10-2016Valery Djermakian

There is some debate among Russian legal professionals about whether “selection inventions” are considered patentable, but the answer seems clear, says Valery Djermakian of Gorodissky & Partners.

Showing 111 to 120 of 280 results

LSIPR